Medical devices, healthcare technology and the business of care
510(k) clearance · K252676

The Circadia C300 System (C300)

Circadia Health, Inc. · Decision date Feb 3, 2026

FDA DECISIONK252676

What did the FDA decide?

FDA records K252676 as a 510(k) premarket notification, with a decision dated Feb 3, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Feb 3, 2026

FDA source record

Regulatory record facts

Identifier
K252676
Regulatory pathway
510(k) premarket notification
Product code
DRT
Decision code
SESE
Decision date
Feb 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Monitor, Cardiac (Incl. Cardiotachometer & Rate Alarm).

Product code
DRT
FDA device class
2

FDA decision timeline

  1. K252676 received

    Application receipt date recorded by FDA.

  2. K252676 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DRT

Product / regulatory recordCompanyPathwayDecision dateSource
Circadia Health, Inc.510(k) clearanceOct 15, 2026FDA
Life Detection Technologies510(k) clearanceSep 25, 2026FDA
Circadia Health, Inc.510(k) clearanceMay 20, 2026FDA
Sleepiz AG510(k) clearanceJan 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Circadia Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
El Segundo, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records